Johnson & Johnson announces new data for Tremfya
JNJ•Johnson & Johnson said new data showed Tremfya delivered durable fistula remission through 48 weeks in Crohn’s disease with perianal fistula. Combined fistula remission in the 100 mg dose group rose from 28% at week 24 to 35% at week 48, while safety findings were consistent with the established profile.
1. Trial findings
Johnson & Johnson announced data showing Tremfya (guselkumab) delivered durable fistula remission through 48 weeks in Crohn’s disease with perianal fistula. Combined fistula remission in the 100 mg dose group increased from 28% at week 24 to 35% at week 48. Safety findings through week 48 were consistent with Tremfya’s established profile in Crohn’s disease.
